A Hybrid Digital-4E Strategy for comorbid migraine and depression: a medical hypothesis on an AI-driven, neuroadaptive, and exposome-aware approach
- PMID: 40510210
- PMCID: PMC12158715
- DOI: 10.3389/fneur.2025.1587296
A Hybrid Digital-4E Strategy for comorbid migraine and depression: a medical hypothesis on an AI-driven, neuroadaptive, and exposome-aware approach
Abstract
Objective: The co-occurrence of migraines and depression presents a critical clinical challenge, affecting up to 50% of individuals with either condition. This comorbidity leads to greater disability, higher healthcare costs, and poorer treatment outcomes than either disorder alone. Despite a bidirectional pathophysiological relationship, current models remain static and fragmented, treating each condition separately. This paper proposes a Hybrid Digital-4E Strategy, deployed on an AI-driven neuroadaptive digital health platform, integrating closed-loop therapy, digital phenotyping, and exposome tracking to enable real-time, personalized care.
Methods: Grounded in the 4E cognition framework (Embodied, Embedded, Enactive, and Extended cognition), this strategy reconceptualizes migraine-depression as an interactive system rather than two separate conditions. The platform integrates real-time biomarker tracking, neuromorphic AI, and precision environmental analytics to dynamically optimize treatment. Adaptive chronotherapy, brain-computer interfaces (BCIs), and virtual reality (VR)-based neuroplasticity training further enhance intervention precision.
Conclusion: A closed-loop, AI-driven neuroadaptive system could improve outcomes by enabling early detection, real-time intervention, and precision care tailored to individual neurophysiological and environmental profiles. Addressing AI bias, data privacy, and clinical validation is crucial for implementation. If validated, this Hybrid Digital-4E Strategy could redefine migraine-depression management, paving the way for precision neuropsychiatry.
Keywords: 4E cognition; AI-driven therapy; closed-loop systems; digital health; exposome; migraine-depression comorbidity; neuroadaptive; precision medicine.
Copyright © 2025 Gazerani.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures
Similar articles
-
Artificial Intelligence in Aesthetic Medicine: Applications, Challenges, and Future Directions.J Cosmet Dermatol. 2025 Jun;24(6):e70241. doi: 10.1111/jocd.70241. J Cosmet Dermatol. 2025. PMID: 40501296 Free PMC article. Review.
-
The doctor and patient of tomorrow: exploring the intersection of artificial intelligence, preventive medicine, and ethical challenges in future healthcare.Front Digit Health. 2025 Apr 3;7:1588479. doi: 10.3389/fdgth.2025.1588479. eCollection 2025. Front Digit Health. 2025. PMID: 40248038 Free PMC article.
-
AI-Guided Cancer Therapy for Patients with Coexisting Migraines.Cancers (Basel). 2024 Oct 31;16(21):3690. doi: 10.3390/cancers16213690. Cancers (Basel). 2024. PMID: 39518129 Free PMC article. Review.
-
Challenging Cognitive Load Theory: The Role of Educational Neuroscience and Artificial Intelligence in Redefining Learning Efficacy.Brain Sci. 2025 Feb 15;15(2):203. doi: 10.3390/brainsci15020203. Brain Sci. 2025. PMID: 40002535 Free PMC article. Review.
-
A systematic review of AI as a digital twin for prostate cancer care.Comput Methods Programs Biomed. 2025 Aug;268:108804. doi: 10.1016/j.cmpb.2025.108804. Epub 2025 May 6. Comput Methods Programs Biomed. 2025. PMID: 40347618 Review.
References
LinkOut - more resources
Full Text Sources